GCNT3 Antibody

What is GCNT3 and what biological functions does it serve?

GCNT3 (Glucosaminyl (N-Acetyl) Transferase 3, Mucin Type) is a glycosyltransferase that synthesizes mucin beta 6 N-acetylglucosaminides. It mediates core 2 and core 4 O-glycan branching, which are crucial steps in mucin-type biosynthesis. Additionally, GCNT3 exhibits I-branching enzyme activity by converting linear into branched poly-N-acetyllactosaminoglycans, thereby introducing the blood group I antigen during embryonic development . The protein plays significant roles in mucin biosynthesis pathways, which are particularly relevant in epithelial tissues and associated pathologies.

What are the common aliases and identification numbers for the GCNT3 gene?

The GCNT3 gene is known by several aliases in scientific literature:

Key identification numbers include:

• HGNC: 4205

• NCBI Gene: 9245

• Ensembl: ENSG00000140297

• OMIM®: 606836

• UniProtKB/Swiss-Prot: O95395

How is GCNT3 expression linked to pathological conditions?

GCNT3 expression has been significantly associated with pancreatic cancer prognosis. Patients with low expression of GCNT3 demonstrated longer survival times compared to those with high expression (median survival: 17.5 vs. 10.5 months, P = 0.036) . In genetically engineered mouse (GEM) models, GCNT3 upregulation (103-fold; P < 0.0001) correlated with increased expression of various mucins (5 to 87-fold; P < 0.04–0.0003) . Furthermore, GCNT3 expression has been positively correlated with drug resistance in cancer cells, suggesting its potential role as a therapeutic target .

Methodological Approaches for GCNT3 Antibody Selection

A robust validation protocol should include:

• Western blot analysis using positive control tissues with known GCNT3 expression (e.g., human duodenum or lymph node lysates)

• Comparison of observed band size (typically 51-57 kDa) with predicted molecular weight (51 kDa)

• Genetic validation using CRISPR-mediated knockout cell lines as negative controls

• RNA interference experiments with GCNT3-specific siRNA followed by antibody detection to confirm specificity

• Cross-validation using multiple antibodies targeting different epitopes of GCNT3

For flow cytometry applications, appropriate fixation with 4% paraformaldehyde and blocking with 10% goat serum are recommended prior to antibody incubation .

How can GCNT3 antibodies be utilized to study mucin-associated drug resistance in cancer?

GCNT3 antibodies can be instrumental in investigating mucin-associated drug resistance through several experimental approaches:

• Expression correlation studies: Utilize immunohistochemistry (IHC) with GCNT3 antibodies to quantify expression levels in patient-derived tumor samples and correlate with treatment response data

• Functional validation: Implement CRISPR-mediated knockout of GCNT3 in cancer cell lines followed by drug sensitivity assays to establish causal relationships

• Mechanistic investigations: Use GCNT3 antibodies in combination with mucin antibodies (e.g., MUC1) to track glycosylation patterns and their impact on drug permeability through confocal microscopy

• Therapeutic target validation: Monitor changes in GCNT3 expression after treatment with glycosylation inhibitors such as talniflumate to confirm target engagement

Research has shown that CRISPR-mediated knockout of GCNT3 in pancreatic cancer cells reduces proliferation and spheroid formation, suggesting potential therapeutic applications .

What is the significance of GCNT3 in pancreatic cancer research and how can antibodies help investigate this relationship?

GCNT3 antibodies are valuable tools in pancreatic cancer research due to the significant correlation between GCNT3 expression and patient survival:

• Prognostic biomarker development: In a study of 88 pancreatic cancer patients, GCNT3 expression assessed by IHC significantly correlated with survival outcomes

• Disease progression monitoring: GCNT3 expression increases progressively during pancreatic cancer development, as observed in PanIN lesions and PDAC tissues from GEM models

• Mucin biosynthesis pathway investigation: Next-generation sequencing revealed GCNT3 upregulation (103.16-fold; P < 0.0001) correlates with increased mucin expression, including Muc4 (50-fold), Muc5ac (87-fold), and Muc6 (67-fold)

• Therapeutic response prediction: Patients with smoking, drinking, or diabetes history comprised 62.9% of the sample with high GCNT3 expression, suggesting potential subgroup identification for targeted therapies

Expression pattern analysis in 103 pancreatic cancer samples showed that 24.2% of male patients and 20.9% of female patients exhibited >50% GCNT3 expression, providing potential stratification criteria for clinical studies .

What are common challenges in GCNT3 antibody-based detection methods and how can they be addressed?

Researchers frequently encounter several challenges when working with GCNT3 antibodies:

• Variable glycosylation patterns affecting epitope accessibility:

  • Solution: Test multiple antibodies targeting different regions of GCNT3 protein

  • Consider enzymatic deglycosylation pretreatment of samples before antibody application

• Cross-reactivity with other glycosyltransferases:

  • Solution: Validate specificity using GCNT3 knockout controls

  • Perform competitive binding assays with recombinant GCNT proteins

• Optimization for specific applications:

  • For Western blot: Observed bands may appear at 51-57 kDa despite the predicted size of 51 kDa due to post-translational modifications

  • For IHC: Antigen retrieval methods should be optimized based on fixation protocols

  • For flow cytometry: Appropriate fixation with 4% paraformaldehyde and blocking with 10% goat serum are recommended

How should researchers approach quantitative analysis of GCNT3 expression using antibody-based methods?

For accurate quantitative assessment of GCNT3 expression:

• Establish appropriate scoring systems:

  • In pancreatic cancer studies, a 5.5% staining score cutoff has been used to differentiate between low and high GCNT3 expression

  • Consider stratification into multiple expression categories (<5%, 5-50%, >50%) for more nuanced analysis

• Implement appropriate controls:

  • Include positive controls with known GCNT3 expression (e.g., human duodenum)

  • Use isotype controls to establish background staining levels

• Validate antibody-based detection with complementary methods:

  • Consider quantitative PCR with SYBR Green for precise measurement

How might GCNT3 antibodies contribute to developing novel therapeutic approaches?

GCNT3 antibodies offer several promising avenues for developing new therapeutic strategies:

• Target validation for small molecule inhibitors:

  • Talniflumate has been identified through in silico docking simulation as a GCNT3 inhibitor with a docking affinity of −8.3 kcal/mol

  • Antibodies can be used to monitor target engagement and efficacy of such inhibitors

• Combinatorial therapy development:

  • Research has shown talniflumate in combination with low-dose gefitinib reduces GCNT3 expression, disrupting mucin production in vivo and in vitro

  • GCNT3 antibodies can help monitor changes in glycosylation patterns during combination treatment

• Prognostic biomarker refinement:

  • GCNT3 expression correlates with survival in pancreatic cancer patients (median survival: 17.5 vs. 10.5 months, P = 0.036)

  • Further stratification of patient populations based on GCNT3 expression patterns may identify specific responder groups

What key questions remain unexplored in GCNT3 research that could benefit from antibody-based approaches?

Several significant knowledge gaps could be addressed using antibody-based techniques:

• Tissue-specific glycosylation patterns:

  • How does GCNT3-mediated glycosylation differ across tissue types and disease states?

  • Can antibodies against specific glycan structures generated by GCNT3 provide more functional insights?

• Regulatory mechanisms:

  • What factors control GCNT3 expression in different biological contexts?

  • Can antibody-based chromatin immunoprecipitation approaches identify transcriptional regulators?

• Interaction networks:

  • Does GCNT3 participate in protein complexes with other glycosyltransferases?

  • Could proximity ligation assays using GCNT3 antibodies reveal novel interaction partners?

• Subcellular localization:

  • How does the distribution of GCNT3 change during disease progression?

  • Can super-resolution microscopy with GCNT3 antibodies provide insights into its trafficking?